Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.

These analyses demonstrated that quarterly or monthly treatment with fremanezumab significantly reduced headache severity and duration in patients with CM or EM, including in patients with documented inadequate response to two to four prior migraine preventive medication classes.